HealthMore in Health→
The Health Care Economy's Surprising Dynamics: Employment, Humira Biosimilars, and Skyrizi's Rise
Key Takeaways
- U.S. workforce would have contracted without the $5.3 trillion health care industry's continued job growth
- Humira biosimilar adoption is slower than predicted due to rebate structures and physician prescribing inertia
- Skyrizi is capturing market volume from both Humira and competitors as AbbVie's internal succession strategy
- Three-way competition between branded Humira, biosimilars, and Skyrizi defies simple cost-reduction narratives
- Health care's growing economic footprint makes drug pricing and employment trends into macroeconomic events
DE
DT Editorial Team··6 min read·via statnews.com